3 recruiting, 1 terminated. 4 Phase 1, 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 4 | Recruiting 3, Terminated 1 |
| Phase 2 | 4 | Recruiting 3, Terminated 1 |
Follow CRISPR Therapeutics AG: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Trial Evaluating Safety, Tolerability and Efficacy of CTX340 in Participants With Hypertension CTX340, Placebo - Hypertension | Phase 1 / Phase 2 | Recruiting | CRISPR Therapeutics AG | 69 | 2026-08-08 | 2026-08-11 |
| Safety and Preliminary Efficacy of CTX112 in Adult Participants With Relapsed/Refractory Hematologic Autoimmune Disease CTX112 - Warm Autoimmune Hemolytic Anemia (WAIHA), ITP - Immune Thrombocytopenia | Phase 1 / Phase 2 | Recruiting | CRISPR Therapeutics AG | 60 | 2026-07-17 | 2026-10-20 |
| A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies CTX112 - B-cell Lymphoma, Non-Hodgkin Lymphoma | Phase 1 / Phase 2 | Recruiting | CRISPR Therapeutics AG | 120 | 2023-03-10 | 2025-11-14 |
| A Safety and Efficacy Study Evaluating CTX110 in Subjects With Relapsed or Refractory B-Cell Malignancies (CARBON) CTX110 - B-cell Malignancy, Non-Hodgkin Lymphoma | Phase 1 / Phase 2 | Terminated | CRISPR Therapeutics AG | 93 | 2019-07-22 | 2025-10-24 |
Lymphoma (2) · Lymphoma, B-Cell (2) · Lymphoma, Non-Hodgkin (2) · Burkitt Lymphoma (1) · Hypertension (1) · Leukemia (1) · Leukemia, Lymphocytic, Chronic, B-Cell (1) · Lymphoma, B-Cell, Marginal Zone (1) · Lymphoma, Follicular (1) · Lymphoma, Mantle-Cell (1) · Purpura, Thrombocytopenic, Idiopathic (1)
United States (4) · Australia (3) · Germany (2) · Spain (2) · Canada (1) · France (1)
Annie Weaver, PhD (1) · Melanie Allen, M.Sc. (1)